Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
作者： Manuela Campiglio , Nicola Normanno , Massimo Di Maio , Francesco Perrone
关键词:
摘要:
elsevier.com
sci-hub.se 参考文章(10)
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
Nicola Normanno, Monica R. Maiello, Antonella De Luca, Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action? Journal of Cellular Physiology. ,vol. 194, pp. 13- 19 ,(2003) , 10.1002/JCP.10194
N. Normanno, M. Campiglio, A. De Luca, G. Somenzi, M. Maiello, F. Ciardiello, L. Gianni, D.S. Salomon, S. Menard, Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Annals of Oncology. ,vol. 13, pp. 65- 72 ,(2002) , 10.1093/ANNONC/MDF020
Stacy L. Moulder, Senthil K. Muthuswamy, Carlos L. Arteaga, F. Michael Yakes, Roberto Bianco, Jean F. Simpson, Epidermal Growth Factor Receptor (HER1) Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2/neu (erbB2)-overexpressing Breast Cancer Cells in Vitro and in Vivo Cancer Research. ,vol. 61, pp. 8887- 8895 ,(2001)
Adam B. Olshen, Patrick A. Treseler, Daniel Polikoff, David M. Jablons, David Stokoe, Chira Chen, Ajay N. Jain, Daniel Pinkel, Joe W. Gray, Pierre P. Massion, Koei Chin, Wen-Lin Kuo, Donna G. Albertson, Genomic Copy Number Analysis of Non-small Cell Lung Cancer Using Array Comparative Genomic Hybridization Implications of the Phosphatidylinositol 3-Kinase Pathway Cancer Research. ,vol. 62, pp. 3636- 3640 ,(2002)
Manuela Campiglio, Alberta Locatelli, Clelia Olgiati, Nicola Normanno, Giulia Somenzi, Lucia Viganò, Marzia Fumagalli, Sylvie Ménard, Luca Gianni, Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level Journal of Cellular Physiology. ,vol. 198, pp. 259- 268 ,(2004) , 10.1002/JCP.10411
Steve Averbuch, Judit Anido, Joan Albanell, Joaquin Arribas, Federico Rojo, Marta Guzmán, Jose Baselga, Pablo Matar, ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clinical Cancer Research. ,vol. 9, pp. 1274- 1283 ,(2003)
Frank A E Kruyt, Giuseppe Giaccone, Maarten L Janmaat, José A Rodriguez, Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clinical Cancer Research. ,vol. 9, pp. 2316- 2326 ,(2003)
Federico Cappuzzo, Vanesa Gregorc, Elisa Rossi, Alessandra Cancellieri, Elisabetta Magrini, Carlo Terenzio Paties, Giovanni Ceresoli, Laura Lombardo, Stefania Bartolini, Cesare Calandri, Marisa De Rosa, Eugenio Villa, Lucio Crinò, Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC Journal of Clinical Oncology. ,vol. 21, pp. 2658- 2663 ,(2003) , 10.1200/JCO.2003.01.039
N Normanno, C Bianco, A De Luca, M R Maiello, D S Salomon, Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocrine-related Cancer. ,vol. 10, pp. 1- 21 ,(2003) , 10.1677/ERC.0.0100001